Treatment Guidelines: Substance Use Disorders

Alcohol Use Disorder

American Association of Psychiatric Pharmacists (AAPP)

• Pharmacist toolkit: Alcohol use disorder (2021)

American Psychiatric Association (APA)

• Practice guideline for the pharmacologic treatment of patients with alcohol use disorder (2018)

American Society of Addiction Medicine (ASAM)

• Clinical practice guideline on alcohol withdrawal management (2020)

Substance Abuse and Mental Health Services Administration (SAMHSA)

• Medication for the treatment of alcohol use disorder: A brief guide (2015)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Treatment of alcohol use disorders in pregnant women (2019)
• Guidelines for biological treatment of substance and related disorders, part 1: alcoholism, first revision (2017)

Stimulant Use Disorder

American Association of Psychiatric Pharmacists (AAPP)

• Pharmacist toolkit: Methamphetamine use disorder (2020)

Substance Abuse and Mental Health Services Administration (SAMHSA)

• Treatment of stimulant use disorders (2020)

Opioid Use Disorder

American Association of Psychiatric Pharmacists (AAPP)

• Understanding Buprenorphine Initiation: Guidance on Dosing Strategies (2022)
• Pharmacist toolkit: Medication management of opioid use disorder (2021)
• Opioid use disorders: Interventions for community pharmacists (2020)
• Naloxone access: A practical guideline for pharmacists (2020)

American Society of Addiction Medicine (ASAM)

• National practice guideline for the treatment of opioid use disorder: focused update (2020)

Canadian Institutes of Health Research (CIHR)

• Management of Opioid Use Disorders: A National Clinical Practice Guideline (2018)

College of Family Physicians of Canada

• Managing Opioid Use Disorder in Primary Care (2019)

Substance Abuse and Mental Health Services Administration (SAMHSA)

• Medications for opioid use disorder (2021)
• Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants (2018)
• Federal guidelines for opioid treatment programs (2015)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Guidelines for the biological treatment of substance use and related disorders, part 2: Opioid dependence (2011)

World Health Organization (WHO)

• Community management of opioid overdose (2014)

Sedative, Hypnotic, or Anxiolytic (Benzodiazepine) Use Disorder

American Association of Psychiatric Pharmacists (AAPP)

• Pharmacist toolkit: Benzodiazepine taper (2021)

Tobacco Use Disorder

Agency for Healthcare Research and Quality (AHRQ)

Treating tobacco use and dependence (2008)

Other

American Association of Psychiatric Pharmacists (AAPP)

• Harm reduction strategies for people who injection drugs: Considerations for pharmacists (2018)

American Psychiatric Association (APA)

• Practice Guideline for the Treatment of Patients With Substance Use Disorders (2006)

British Association of Psychopharmacology (BAP)

• BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP (2012)

Substance Abuse and Mental Health Services Administration (SAMHSA)

• Treating substance use disorder in older adults (2020)
• Detoxification and Substance Abuse Treatment (2015)

Veterans Affairs/Department of Defense

• VA/DoD clinical practice guideline for the management of substance use disorders (2021)

World Health Organization (WHO)

• Guidelines for the identification and management of substance use and substance use disorders in pregnancy (2014)

Reviewer 1: Austin Smith, PharmD, BCPP
Reviewer 2: Carly Rainey, PharmD, BCPS
2023-2024 AAPP Resident and New Practitioner Committee